Story · Medicine & Biotech
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
2 outlets · first reported by STAT News on · latest · 3 hours of coverage · 2 countries
The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved… (STAT News)
Coverage, in order
-
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved…
-
FDA won't approve Summit, Akeso's ivonescimab
FDA won't approve Summit, Akeso's ivonescimab Phil.Taylor Sun, 15/11/2026 - 18:23
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.